Eli Lilly Earnings Top, 2025 Guidance Strong, But Weight-Loss Drug Sales MissInvestors Business Daily • 02/06/25
Eli Lilly forecasts 2025 profit largely above estimates on launch of weight-loss drug in new marketsReuters • 02/06/25
Eli Lilly Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate AnalystsBenzinga • 02/06/25
Curious about Lilly (LLY) Q4 Performance? Explore Wall Street Estimates for Key MetricsZacks Investment Research • 02/03/25
With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?The Motley Fool • 02/02/25
FDA Approval of Eli Lilly's Omvoh for Crohn's Disease Adds a New Option, but Uptake May be Hampered by US Gastroenterologists' Brand Preferences Among the IL-23 Class, According to Spherix Global InsightsGlobeNewsWire • 01/31/25
Billionaire Philippe Laffont Just Sold Top Artificial Intelligence Stocks Nvidia and AMD and Piled Into 2 Players Dominating Another High-Growth Billion-Dollar IndustryThe Motley Fool • 01/31/25
Next Generation Donors' Charitable Giving Interests and Approaches Examined in New Study From Indiana University Lilly Family School of Philanthropy and DAFgiving360Business Wire • 01/29/25
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shotBusiness Insider • 01/26/25